Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:ageRange |
18 Years to 65 Years
|
| gptkbp:allocates |
Randomized
|
| gptkbp:clinicalTrialPhase |
Phase 2
|
| gptkbp:completedIn |
August 2011
|
| gptkbp:conditionStudied |
gptkb:Schizophrenia
|
| gptkbp:enrollment |
415
|
| gptkbp:gender |
All
|
| gptkbp:intervention |
gptkb:drug
RO4917838 |
| gptkbp:location |
gptkb:Asia
gptkb:Europe gptkb:United_States |
| gptkbp:mask |
Double-blind
|
| gptkbp:primaryOutcomeMeasure |
Change from baseline in PANSS total score at Week 6
|
| gptkbp:purpose |
Treatment
|
| gptkbp:recognizedBy |
gptkb:NCT01035255
|
| gptkbp:secondaryOutcomeMeasure |
Change from baseline in CGI-S score at Week 6
|
| gptkbp:sponsor |
gptkb:Hoffmann-La_Roche
|
| gptkbp:startDate |
December 2009
|
| gptkbp:status |
completed
|
| gptkbp:studyType |
Interventional
|
| gptkbp:title |
A Study of RO4917838 in Patients With Schizophrenia
|
| gptkbp:url |
https://clinicaltrials.gov/ct2/show/NCT01035255
|
| gptkbp:bfsParent |
gptkb:PARADIGM-HF
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
NCT01035255
|